This may reflect the fact that TNF-α therapies for IBD are aimed at efficiently clearing TNF-α, while IL-10 therapies must increase IL-10 and recombinant IL-10 is likely too rapidly cleared from the circulation after in vivo administration to produce a uniform protection [53]. This evidence concerns the gene TNF and inflammatory bowel disease.